Palmitoylethanolamide
Home »
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide made inside the body when necessary. Since its discovery in 1954 there have been more than five hundred studies aimed at presenting the benefits and safety of palmitoylethanolamide.
There have been several surges in research popularity, mainly coming from the possibility of practical use of palmitoylethanolamide as treatment. The first products came to the market in the 1970s, after the initial set of research that showed the benefits of PEA. However, their purity was not the best and their price was too high.
New spark in popularity came after the research of Nobel Prize winner Rita Levi-Montalcini who discovered part of the mechanism behind the effectiveness of palmitoylethanolamide related to mast cells. This led to a new period of research and new products which came to the market.
Success of those results and new research into the endocannabinoid system led us to the current trend of a great number of recent research papers and studies into palmitoylethanolamide and its benefits and effects. In the past few years there have been more studies regarding palmitoylethanolamide than ever before.
Palmitoylethanolamide (PEA) products
There have been many PEA products on the market since it was discovered back in the 1950s. However, the latest discoveries brought us the most advanced ones.
We are proud to offer palmitoylethanolamide products of pharmaceutical-grade quality that provide unmatched purity with nothing but PEA in vegetarian capsules.
However, this does not mean we thought our work was over. Palmitoylethanolamide has one issue that hampers its innate efficacy. Its half-life is very short as it is quickly degraded by two very efficient enzymes in the body – fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amide hydrolase (NAAA). This means that the positive effects of palmitoylethanolamide are limited by the efficacy of these enzymes.
We set out to provide the market with a product that is more bioavailable and thus more efficient. After a year of research that tested numerous kinds of improvements of bioavailability without jeopardizing safety and efficacy, we came up with liposomal palmitoylethanolamide which greatly improves bioavailability and absorption. This is so because liposome membranes and cell membranes are biocompatible, so encapsulating palmitoylethanolamide inside a liposome means that PEA is protected from the enzymes and stomach acids and that it is delivered straight to the cells, as well as fully absorbed, since phospholipids of the cell membrane readily accept phospholipids of the liposome membrane.
We are still not done with advancements. We are currently developing dry liposomes which are intended to combine the ease of use of capsules with the bioavailability benefits of liposomal delivery.
You can read about our products and PEA in general below
